GlassScriptPhysician profile
Jared L Wallace
NPI 1063746667
$7,231.51
in general payments reported to CMS, 2019-2025
30 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,006 · 2022: $798 · 2023: $1,139 · 2024: $1,205 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486 · Travel and Lodging: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.36 |
| Travel and Lodging | $1,941.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,218.21 | 2022-2025 | Minimed 780g |
| Abbvie INC. | $1,347.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $785.51 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $428.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $387.58 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $283.12 | 2021-2025 | |
| Amgen INC. | $244.68 | 2022-2025 | Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.31 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $135.55 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Xeris Pharmaceuticals, INC. | $127.70 | 2023-2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $107.15 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $106.90 | 2022-2024 | Austedo Xr, Austedo |
| Averitas Pharma INC. | $91.65 | 2024-2025 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $86.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.07 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $74.84 | 2024-2025 | Sublocade |
| Philips North America LLC | $58.79 | 2022 | |
| Exact Sciences Corporation | $58.06 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $51.00 | 2022-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $42.05 | 2021 | |
| Merck Sharp & Dohme LLC | $40.77 | 2021-2023 | Verquvo, Belsomra, Januvia |
| Endo Pharmaceuticals INC. | $40.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.57 | 2021-2022 | |
| Eisai INC. | $30.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $26.75 | 2022 | |
| Abbott Laboratories | $25.76 | 2025 | Id Now Instrument |
| Corcept Therapeutics | $25.61 | 2025 | Korlym |
| Insulet Corporation | $25.12 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $17.53 | 2021 | |
| Dexcom, INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.